Transformed but Not Cured

In December 2023, the U.S. Food and Drug Administration approved gene-editing therapies as sickle cell disease treatments. Such approvals for gene-editing not only mark radical scientific innovations for populations living with sickle cell disease (SCD) across the United States but also generate an expectation of a potential cure-the end or eradication of an illness and its effects. This essay, however, cautions against framing gene-editing therapy as a "cure" for SCD. Our argument illustrates that, even if gene editing is proven to permanently normalize the hematologic function of the body, there are other painful aspects of SCD that gene editing is unable to transform. Scientific researchers and health care practitioners could benefit from further bioethical consideration of the effects of using curative language with regards to SCD. The curative framing can easily generate misunderstandings in patient-provider communication and elicit unrealistic expectations. Raising awareness about the importance of how gene-editing therapies for SCD are described and about the need to discuss their limitations can prevent further harm

Alternative medicine · Bioethics · Clinical trial · Disease · Food and drug administration · Framing (construction) · Genome editing · Health care · Hemoglobinopathy · CRISPR and Genetic Engineering · Neuroethics, Human Enhancement, Biomedical Innovations · Virus-based gene therapy research

• Epistemic Injustice

  Miranda Fricker•Epistemic Injustice•2007

  Incluir item

• I’m not hep C free’

  D Kagan, Kate Seear et al.•Medical Humanities•2023

  Incluir item

• The meaning of the survivor identity for women with breast cancer

  Open Access•Karen Kaiser•Social Science & Medicine•2008

  Incluir item